Characterization of the Immune Resistance of Severe Acute Respiratory Syndrome Coronavirus 2 Mu Variant and the Robust Immunity Induced by Mu Infection

Ecuador-COVID19 Consortium; Genotype to Phenotype Japan (G2P-Japan) Consortium

doi:10.1093/infdis/jiac053

Characterization of the Immune Resistance of Severe Acute Respiratory Syndrome Coronavirus 2 Mu Variant and the Robust Immunity Induced by Mu Infection

Ecuador-COVID19 Consortium
, Genotype to Phenotype Japan (G2P-Japan) Consortium

The University of Tokyo
Graduate School of Medicine
Tokai University
Kyoto University
Chiba University
Hiroshima University
Hokkaido University
Kumamoto University
University of Miyazaki
National Institute of Infectious Diseases
Tokyo Metropolitan Institute of Public Health
Universidad San Francisco de Quito
Laboratorio INTERLAB
Universidad Espíritu Santo, Ecuador
Universidad Internacional del Ecuador
Dr. Marco Albuja Centros Médicos
Japan Science and Technology Agency

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Background: We have recently revealed that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Mu variant shows a pronounced resistance to antibodies elicited by natural SARS-CoV-2 infection and vaccination. Methods: However, it remains unclear which mutations determine the resistance of SARS-CoV-2 Mu to antiviral sera. In addition, it is unclear how SARS-CoV-2 Mu infection induces antiviral immunity. Results: In this study, we reveal that the 2 mutations in the SARS-CoV-2 Mu spike protein, YY144-145TSN and E484K, are responsible for the resistance to coronavirus disease 2019 convalescent sera during early 2020 and vaccine sera. Conclusions: It is notable that the convalescent sera of SARS-CoV-2 Mu-infected individuals are broadly antiviral against Mu as well as other SARS-CoV-2 variants of concern and interest.

Original language	English
Pages (from-to)	1200-1203
Number of pages	4
Journal	Journal of Infectious Diseases
Volume	226
Issue number	7
DOIs	https://doi.org/10.1093/infdis/jiac053
State	Published - 1 Oct 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

COVID-19
Mu variant
SARS-CoV-2
immune resistance

Access to Document

10.1093/infdis/jiac053

Cite this

@article{3575d3c4071d4428addf1ac7d7ce7909,

title = "Characterization of the Immune Resistance of Severe Acute Respiratory Syndrome Coronavirus 2 Mu Variant and the Robust Immunity Induced by Mu Infection",

abstract = "Background: We have recently revealed that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Mu variant shows a pronounced resistance to antibodies elicited by natural SARS-CoV-2 infection and vaccination. Methods: However, it remains unclear which mutations determine the resistance of SARS-CoV-2 Mu to antiviral sera. In addition, it is unclear how SARS-CoV-2 Mu infection induces antiviral immunity. Results: In this study, we reveal that the 2 mutations in the SARS-CoV-2 Mu spike protein, YY144-145TSN and E484K, are responsible for the resistance to coronavirus disease 2019 convalescent sera during early 2020 and vaccine sera. Conclusions: It is notable that the convalescent sera of SARS-CoV-2 Mu-infected individuals are broadly antiviral against Mu as well as other SARS-CoV-2 variants of concern and interest.",

keywords = "COVID-19, Mu variant, SARS-CoV-2, immune resistance",

author = "\{Ecuador-COVID19 Consortium\} and \{Genotype to Phenotype Japan (G2P-Japan) Consortium\} and Keiya Uriu and Pa{\'u}l C{\'a}rdenas and Erika Mu{\~n}oz and Veronica Barragan and Yusuke Kosugi and Kotaro Shirakawa and Akifumi Takaori-Kondo and Jumpei Ito and Daichi Yamasoba and Izumi Kimura and Mai Suganami and Akiko Oide and Miyabishara Yokoyama and Mika Chiba and So Nakagawa and Jiaqi Wu and Miyoko Takahashi and Yasuhiro Kazuma and Ryosuke Nomura and Yoshihito Horisawa and Kayoko Nagata and Yohei Yanagida and Yugo Kawai and Yusuke Tashiro and Atsushi Kaneda and Nakada, \{Taka Aki\} and Motoaki Seki and Ryoji Fujiki and Tadanaga Shimada and Kiyoshi Hirahara and Koutaro Yokote and Toshinori Nakayama and Takashi Irie and Ryoko Kawabata and Nanami Morizako and Takasuke Fukuhara and Kenta Shimizu and Kana Tsushima and Haruko Kubo and Terumasa Ikeda and Chihiro Motozono and Hesham Nasser and Sully M{\'a}rquez and Bel{\'e}n Prado-Vivar and M{\'o}nica Becerra-Wong and Mateo Carvajal and Gabriel Trueba and Patricio Rojas-Silva and Michelle Grunauer and Guadalupe, \{Juan Jos{\'e}\}",

year = "2022",

month = oct,

day = "1",

doi = "10.1093/infdis/jiac053",

language = "Ingl{\'e}s",

volume = "226",

pages = "1200--1203",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "7",

}

Characterization of the Immune Resistance of Severe Acute Respiratory Syndrome Coronavirus 2 Mu Variant and the Robust Immunity Induced by Mu Infection. / Ecuador-COVID19 Consortium; Genotype to Phenotype Japan (G2P-Japan) Consortium.
In: Journal of Infectious Diseases, Vol. 226, No. 7, 01.10.2022, p. 1200-1203.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Characterization of the Immune Resistance of Severe Acute Respiratory Syndrome Coronavirus 2 Mu Variant and the Robust Immunity Induced by Mu Infection

AU - Ecuador-COVID19 Consortium

AU - Genotype to Phenotype Japan (G2P-Japan) Consortium

AU - Uriu, Keiya

AU - Cárdenas, Paúl

AU - Muñoz, Erika

AU - Barragan, Veronica

AU - Kosugi, Yusuke

AU - Shirakawa, Kotaro

AU - Takaori-Kondo, Akifumi

AU - Ito, Jumpei

AU - Yamasoba, Daichi

AU - Kimura, Izumi

AU - Suganami, Mai

AU - Oide, Akiko

AU - Yokoyama, Miyabishara

AU - Chiba, Mika

AU - Nakagawa, So

AU - Wu, Jiaqi

AU - Takahashi, Miyoko

AU - Kazuma, Yasuhiro

AU - Nomura, Ryosuke

AU - Horisawa, Yoshihito

AU - Nagata, Kayoko

AU - Yanagida, Yohei

AU - Kawai, Yugo

AU - Tashiro, Yusuke

AU - Kaneda, Atsushi

AU - Nakada, Taka Aki

AU - Seki, Motoaki

AU - Fujiki, Ryoji

AU - Shimada, Tadanaga

AU - Hirahara, Kiyoshi

AU - Yokote, Koutaro

AU - Nakayama, Toshinori

AU - Irie, Takashi

AU - Kawabata, Ryoko

AU - Morizako, Nanami

AU - Fukuhara, Takasuke

AU - Shimizu, Kenta

AU - Tsushima, Kana

AU - Kubo, Haruko

AU - Ikeda, Terumasa

AU - Motozono, Chihiro

AU - Nasser, Hesham

AU - Márquez, Sully

AU - Prado-Vivar, Belén

AU - Becerra-Wong, Mónica

AU - Carvajal, Mateo

AU - Trueba, Gabriel

AU - Rojas-Silva, Patricio

AU - Grunauer, Michelle

AU - Guadalupe, Juan José

PY - 2022/10/1

Y1 - 2022/10/1

N2 - Background: We have recently revealed that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Mu variant shows a pronounced resistance to antibodies elicited by natural SARS-CoV-2 infection and vaccination. Methods: However, it remains unclear which mutations determine the resistance of SARS-CoV-2 Mu to antiviral sera. In addition, it is unclear how SARS-CoV-2 Mu infection induces antiviral immunity. Results: In this study, we reveal that the 2 mutations in the SARS-CoV-2 Mu spike protein, YY144-145TSN and E484K, are responsible for the resistance to coronavirus disease 2019 convalescent sera during early 2020 and vaccine sera. Conclusions: It is notable that the convalescent sera of SARS-CoV-2 Mu-infected individuals are broadly antiviral against Mu as well as other SARS-CoV-2 variants of concern and interest.

AB - Background: We have recently revealed that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Mu variant shows a pronounced resistance to antibodies elicited by natural SARS-CoV-2 infection and vaccination. Methods: However, it remains unclear which mutations determine the resistance of SARS-CoV-2 Mu to antiviral sera. In addition, it is unclear how SARS-CoV-2 Mu infection induces antiviral immunity. Results: In this study, we reveal that the 2 mutations in the SARS-CoV-2 Mu spike protein, YY144-145TSN and E484K, are responsible for the resistance to coronavirus disease 2019 convalescent sera during early 2020 and vaccine sera. Conclusions: It is notable that the convalescent sera of SARS-CoV-2 Mu-infected individuals are broadly antiviral against Mu as well as other SARS-CoV-2 variants of concern and interest.

KW - COVID-19

KW - Mu variant

KW - SARS-CoV-2

KW - immune resistance

UR - https://www.scopus.com/pages/publications/85129088227

U2 - 10.1093/infdis/jiac053

DO - 10.1093/infdis/jiac053

M3 - Artículo

C2 - 35176774

AN - SCOPUS:85129088227

SN - 0022-1899

VL - 226

SP - 1200

EP - 1203

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 7

ER -

Characterization of the Immune Resistance of Severe Acute Respiratory Syndrome Coronavirus 2 Mu Variant and the Robust Immunity Induced by Mu Infection

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this